| Clinical pharmacology of portal hypertension. | |
| | |
MedLine Citation:
|
PMID: 20951924 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Portal hypertension is an increase in pressure in the portal vein and its tributaries. It is defined as a portal pressure gradient (the difference in pressure between the portal vein and the hepatic veins) greater than 5 mm Hg. Although this gradient defines portal hypertension, a gradient of 10 mm Hg or greater defines clinically significant portal hypertension, because this pressure gradient predicts the development of varices, decompensation of cirrhosis, and hepatocellular carcinoma. The most direct consequence of portal hypertension is the development of gastroesophageal varices that may rupture and lead to the development of variceal hemorrhage. This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage. |
| | |
Authors:
|
Cecilia Miñano; Guadalupe Garcia-Tsao |
Related Documents
:
|
8440794 - Comparison of the hemodynamic effects of hydroxocobalamin and cobalt edetate at equipot... 1129264 - Vasoactive intestinal polypoptide: inactivation in liver and potentiation in lung of an... 8435014 - Exclusion criteria and outcome in pressure reduction of intussusception. 20630674 - Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology. 8538824 - Diagnosis and therapeutic aspects of stroke. 12142194 - Hemodynamics optimization during off-pump coronary artery bypass: the 'no compression' ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Gastroenterology clinics of North America Volume: 39 ISSN: 1558-1942 ISO Abbreviation: Gastroenterol. Clin. North Am. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-10-18 Completed Date: 2011-02-04 Revised Date: 2012-10-09 |
Medline Journal Info:
|
Nlm Unique ID: 8706257 Medline TA: Gastroenterol Clin North Am Country: United States |
Other Details:
|
Languages: eng Pagination: 681-95 Citation Subset: IM |
Copyright Information:
|
Published by Elsevier Inc. |
Affiliation:
|
Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage,
therapeutic use Fibrosis / complications Hemorrhage / drug therapy, prevention & control, surgery Humans Hypertension, Portal / drug therapy*, etiology, physiopathology* Liver / blood supply Randomized Controlled Trials as Topic Somatostatin / administration & dosage, analogs & derivatives, therapeutic use Varicose Veins / physiopathology, prevention & control Vasoconstrictor Agents / therapeutic use Vasodilator Agents / therapeutic use Vasopressins / administration & dosage, therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
K24 DK002727-10/DK/NIDDK NIH HHS; P30 DK034989/DK/NIDDK NIH HHS; P30 DK034989-277468/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Vasoconstrictor Agents; 0/Vasodilator Agents; 11000-17-2/Vasopressins; 51110-01-1/Somatostatin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New pharmacologic therapies in chronic hepatitis B.
Next Document: Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and col...